Evidence map›Paper›PMID 40124701›Full record

ArticleOxford medical case reports2025

PD-1/PD-L1 checkpoint inhibitor-induced encephalitis in patients with lung adenocarcinoma: a report of three cases.

Takayo Ota, Masaaki Terashima, Yukihiro Hamada, Shuichi Ueno, Shigeru Kawai, Noriko Tanaka, Kaoru Matsui, Noriyuki Masuda

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Oxford medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Takayo OtaDepartment of Breast Medical Oncology, Izumi City General Hospital, 4-5-1, Wake, Izumi, Osaka, 594-0073, Japan.ORCID https://orcid.org/0000-0003-1630-8301
Masaaki TerashimaDepartment of Medical Oncology, Izumi City General Hospital, 4-5-1, Wake, Izumi, Osaka, 594-0073, Japan.
Yukihiro HamadaDepartment of Neurology, Izumi City General Hospital, 4-5-1, Wake, Izumi, Osaka, 594-0073, Japan.
Shuichi UenoDepartment of Neurology, Izumi City General Hospital, 4-5-1, Wake, Izumi, Osaka, 594-0073, Japan.
Shigeru KawaiDepartment of Neurology, Izumi City General Hospital, 4-5-1, Wake, Izumi, Osaka, 594-0073, Japan.
Noriko TanakaDepartment of Radiology, Izumi City General Hospital, 4-5-1, Wake, Izumi, Osaka, 594-0073, Japan.
Kaoru MatsuiDepartment of Breast Medical Oncology, Izumi City General Hospital, 4-5-1, Wake, Izumi, Osaka, 594-0073, Japan.
Noriyuki MasudaDepartment of Breast Medical Oncology, Izumi City General Hospital, 4-5-1, Wake, Izumi, Osaka, 594-0073, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitor (ICI)-induced encephalitis is rare. We present three cases of encephalitis associated with ICIs in lung adenocarcinoma patients. These patients presented with a variety of symptoms, but one of the common symptoms for all patients was loss of consciousness. All patients responded well to steroid treatment and survived longer than one month after the onset of symptoms. These cases highlight the difficulties in diagnosing encephalitis based only on clinical information, and timely management is important to improve survival. Opportunistic infections also have to be ruled out to diagnose ICI-induced encephalitis especially when brain metastases co-exist.

Indexed as

brain metastasescytomegalovirusencephalitisimmune checkpoint inhibitorslung adenocarcinomaPD-1/PD-L1 inhibitors

Identifiers

PMID40124701
PMCPMC11924394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.